Managing Information Overload - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Managing Information Overload
Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise's diverse and discrete technology applications.

Pharmaceutical Technology Europe
Volume 23, Issue 8

Kutay Tanir/Getty Images
Data is information waiting to happen, but today's global pharmaceutical companies are riddled with data—so much that their numerous functions and disparate systems struggle to know what to do with all of it. Worse still, these data are usually disconnected, duplicated and, all too often, inaccurate.

Data is generated by the day-to-day activities that take place in each department. Regulatory operations personnel, for example, produce documents, develop submissions and file them in for approval. However, a submission begins long before the documents themselves are created. The process commences with the generation of concepts that get encapsulated into documents, which ultimately form the regulatory submission. Submissions become part of a portfolio across multiple nations, with concomitant licences that must be managed. In most cases, data gathering is managed locally, with regulatory departments drawing on the minimal amount of information needed to adhere to requirements or to track commitments. What is often missing is the ability to aggregate information across the enterprise so that it can be used to conduct more predictive work, such as project planning across the portfolio, resource planning, and pre- and post-marketing activities. In so doing, companies can manage their activities more holistically.

Other industries have been quicker to grasp the importance of information management. Perhaps one of the best examples is the automobile industry; for example, when problems arise with a particular model, the manufacturer can respond quickly by linking manufacturing information with warranty information. When a manufacturer spots a trend, such as a faulty part, it can both ensure that its dealers are ready with the new parts and send out relevant recall letters, thereby helping to minimise any escalation in cost.

Information overload

Pharmaceutical companies are aware of the data they generate and capture. According to a survey by the consulting group Ovum (1), the pharmaceutical industry is ahead of other industries when it comes to adopting enterprise applications, such as customer relationship management (CRM) and enterprise resource planning (ERP) solutions, but lags behind with business intelligence solutions such as regulatory tracking and management systems that can harness data productively.

Poor information management can create a bottleneck for companies on multiple levels, as well as add unnecessary cost burdens. Take the cost of storage, for example; failing to manage data results in the retention of redundant information and records, which occupy storage space within a system. Then there's the time cost associated with chasing information needed to meet regulatory requirements or to make a business or strategic decision.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here